Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Versanis Bio, and Emergence Therapeutics, Looking at Q2, Eli Lilly’s revenue of $11.3 billion reflected a solid 36% y-o-y growth. This can be attributed to market share gains for some of its ...

Versanis Bio, and Emergence Therapeutics. Even in Q3 2024, Eli Lilly recorded $2.8 billion IPR&D charges related to the acquisition of Morphic Holding. Looking forward, Eli Lilly lowered its sales ...

Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were ...

Christi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job at Gilead's Kite cancer immunotherapy unit. Shares in Lilly were down almost 4% after ...

Eli Lilly & Co.’s stock was on pace for its worst ... which the company acquired last year with its deal for Versanis Bio, ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development facility in Lebanon, Indiana expected to open in late 2027. Fatty liver ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

(RTTNews) - ViaNautis Bio Monday announced partnership with Eli Lilly and Company (LLY) to use ViaNautis' proprietary drug delivery platform polyNaut in delivering genetic medicines. ViaNautis ...

In 2023, Zepbound maker Eli Lilly (LLY) acquired Versanis Bio, a privately held biopharma whose lead asset is bimagrumab, a ...

Eli Lilly's Lotus Mallbris Dr Lotus Mallbris, vice president and immunology platform team leader, Lilly Bio-Medicines, said: "Many people with this chronic, debilitating disease are still ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Tourmaline Bio (TRML – Research ...